U.S. Food and Drug Administration (FDA)

Sep 12, 2018

Aimovig of Amgen commence robust for migraine treatment The U.S. Food and Drug Administration (FDA) has given the approval to preventative migraine treatment, Aimovig of Amgen. Aimovig has a price of USD 6,900 per year, but according to analysis of sales, it gives information that migraine treatment is making its wa...

Sep 11, 2018

Nucala of GlaxoSmithKline exhibits splendid benefits to other IL-5 Inhibitors in Asthma, however flunks as a COPD Drug A Complete Response Letter is received by GSK from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as COPD treatment. Nucala, which targets the IL-5 pathway, was initially appro...